Oryzon Genomics

SP: ORY

€140.3m market cap

€3.59 last close

Oryzon Genomics is a Spanish biotech focused on epigenetics. Iadademstat (ORY-1001, Phase IIa) is being explored for acute leukaemias and SCLC; Vafidemstat (ORY-2001) is in Phase IIa for AD, MS and aggression, and ORY-3001 is being developed for certain orphan indications.

Investment summary

Oryzon’s expertise lies in developing small molecule inhibitors for epigenetic targets. Oryzon’s lead CNS product vafidemstat (ORY-2001), a dual LSD1/MAOB inhibitor, targets Alzheimer’s disease (Phase IIa initiated), multiple sclerosis (Phase IIa initiated) and other neurodegenerative indications. Results from both trials are expected in 2019. Oryzon has also initiated a Phase IIa trial studying vafidemstat (ORY-2001) in aggressiveness. The lead oncology product iadademstat (ORY-1001) is a specific LSD1 inhibitor with positive data from the Phase I/IIa in acute myeloid leukaemia (AML) announced in December 2016. A Phase IIa trial in AML and Phase IIa trial in SCLC have recently initiated.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2016A 5.0 (3.7) (4.7) (17.02) N/A N/A
2017A 4.3 (3.5) (4.6) (14.29) N/A N/A
2018E 7.0 (4.7) (5.6) (9.23) N/A N/A
2019E 6.3 (6.4) (7.3) (18.56) N/A N/A
Last updated on 19/02/2019
Industry outlook

Epigenetics is a relatively young field in terms of drug development. HDACs were among the first epigenetic therapeutics brought to market, and although effective, they have side effects. Oryzon is among the leading clinical stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and are expected to show a favourable safety/efficacy profile.

Last updated on 19/02/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (€m) 11.6
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 31.3 23.4 35.3
Relative* 30.4 21.7 45.2
52-week high/low €5.0/€2.1
*% relative to local index
Key management
Carlos Buesa CEO

Content on Oryzon Genomics